2267 On Other Exchanges
Symbol
Exchange
2267 is not on other exchanges.

yakult honsha co ltd (2267) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for YAKULT HONSHA CO LTD (2267)
\

Related News

No related news articles were found.

yakult honsha co ltd (2267) Related Businessweek News

View More BusinessWeek News

yakult honsha co ltd (2267) Details

Yakult Honsha Co.,Ltd. manufactures and sells food and beverage products, cosmetics, pharmaceuticals, and others. It operates through Food and Beverages (Japan), Food and Beverages (The Americas), Food and Beverages (Asia and Oceania), Food and Beverages (Europe), Pharmaceuticals, and Others segments. The company offers fermented milk drinks, juices, noodles, etc. through its home delivery and retail store channels. It also provides pharmaceutical products, such as Elplat, an antineoplastic drug for the treatment of colorectal cancer; Campto, a antineoplastic drug; Gemcitabine Yakult, an antineoplastic antimetabolite; Zoledronic acid Yakult, a bone resorption inhibitor; and Docetaxel Yakult, a generic taxoid antineoplastic drug. In addition, the company offers cosmetics and skin care products under the Parabio, Revecy, and Revecy White brand names; and operates and manages the Tokyo Yakult Swallows, a professional baseball team. Yakult Honsha Co.,Ltd. was founded in 1935 and is headquartered in Tokyo, Japan.

25,993 Employees
Last Reported Date: 06/21/18
Founded in 1935

yakult honsha co ltd (2267) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

yakult honsha co ltd
Verastem Inc. Signs Exclusive License Agreement with and Yakult Honsha Co., Ltd. for the Development and Commercialization of Duvelisib in Japan

Verastem Inc. and Yakult Honsha Co. Ltd. announced their entry into an exclusive licensing agreement for Yakult to develop and commercialize Verastem’s duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase-delta and PI3K-gamma, for the treatment, prevention or diagnosis of all oncology indications in Japan. Verastem’s New Drug Application for duvelisib is currently under review with the U.S. Food and Drug Administration and is seeking full approval for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and accelerated approval for the treatment of relapsed or refractory follicular lymphoma. Verastem also announced that the FDA had accepted the NDA for filing with Priority Review. Under the terms of the agreement, Verastem will receive a one-time upfront payment of $10 million from Yakult. Verastem is eligible to receive up to an additional $90 million if certain future pre-specified development and commercialization milestones are successfully achieved by Yakult, plus double-digit royalties based on future net sales of duvelisib in Japan. In exchange, Yakult will receive exclusive rights to develop and commercialize duvelisib in Japan, at its own cost and expense. Yakult will also fund certain global development costs on a pro-rata basis. Verastem will retain all rights to duvelisib outside of Japan.

Yakult Honsha Co.,Ltd., Annual General Meeting, Jun 20, 2018

Yakult Honsha Co.,Ltd., Annual General Meeting, Jun 20, 2018.

Yakult Honsha Co.,Ltd. Announces Consolidated and Non-Consolidated Earnings Results for the Full Year Ended March 31, 2018; Provides Consolidated and Non-Consolidated Earnings Guidance for the Full Year Ending March 31, 2019

Yakult Honsha Co.,Ltd. announced consolidated and non-consolidated earnings results for the full year ended March 31, 2018. For the year, on consolidated basis, the company announced net sales of JPY 401,569 million against JPY 378,307 million a year ago. Operating income was JPY 43,463 million against JPY 37,281 million a year ago. Income before income taxes and minority interests was JPY 53,481 million against JPY 48,681 million a year ago. Profit attributable to owners of parent was JPY 34,064 million against JPY 30,154 million a year ago. Capital investments were JPY 23,304 million against JPY 23,365 million a year ago. Cash flows from operating activities were JPY 61,989 million against JPY 59,998 million a year ago. For the year, on non-consolidated basis, the company announced net sales of JPY 177,535 million against JPY 173,683 million a year ago. Operating income was JPY 2,215 million against JPY 782 million a year ago. Income before income taxes was JPY 15,121 million against JPY 11,563 million a year ago. Profit was JPY 13,908 million against JPY 10,088 million a year ago. Capital investments were JPY 7,901 million against JPY 11,149 million a year ago. The company provided consolidated and non-consolidated earnings guidance for the full year ending March 31, 2019. For the full year, on consolidated basis, the company expects to report net sales of JPY 418,000 million, operating income of JPY 46,500 million, ordinary income of JPY 56,500 million and profit attributable to owners of parent of JPY 35,500 million. Capital investments expected to be JPY 33,000 million. Depreciation and amortization expected to be JPY 22,000 million. For the full year, on non-consolidated basis, the company expects to report net sales of JPY 179,500 million, operating income of JPY 1,500 million, ordinary income of JPY 15,500 million and net income of JPY 14,000 million. Capital investments expected to be JPY 7,200 million. Depreciation and amortization expected to be JPY 9,430 million.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

2267 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2267.
View Industry Companies
 

Industry Analysis

2267

Industry Average

Valuation 2267 Industry Range
Price/Earnings 35.5x
Price/Sales 3.0x
Price/Book 3.4x
Price/Cash Flow 36.9x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact YAKULT HONSHA CO LTD, please visit www.yakult.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.